Evidence map›Paper›PMID 42477572›Full record

ArticleBMC cancer2026

Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort.

Richard Phillips, Harry Daniels, Marie Quinlan, Ali Suwaidan, Kaushal Maru, Jake Hancock, Mabel Teng, Jasvinder Kaur, Yuk Ting Ma, Sean Dulloo and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Richard PhillipsDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK. rep199@student.bham.ac.uk.ORCID http://orcid.org/0000-0002-8978-9743
Harry DanielsDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK.
Marie QuinlanDepartment of Oncology and Radiotherapy, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Ali SuwaidanDepartment of Medical Oncology, University Hospitals Leicester, Leicester, UK.
Kaushal MaruDepartment of Medical Oncology, University Hospitals Birmingham NHS Trust, Edgbaston, Birmingham, UK.
Jake HancockDepartment of Medical Oncology, University Hospitals Birmingham NHS Trust, Edgbaston, Birmingham, UK.
Mabel TengDepartment of Medical Oncology, University Hospitals Birmingham NHS Trust, Edgbaston, Birmingham, UK.
Jasvinder KaurDepartment of Medical Oncology, University Hospitals Birmingham NHS Trust, Edgbaston, Birmingham, UK.
Yuk Ting MaDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK.
Sean DullooDepartment of Medical Oncology, University Hospitals Leicester, Leicester, UK.
Sadaqat HussainDepartment of Medical Oncology, University Hospitals Leicester, Leicester, UK.
Basma GreefDepartment of Oncology and Radiotherapy, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Shivan SivakumarDepartment of Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe IMbrave150 trial established atezolizumab plus bevacizumab (ATE/BEV) as first-line standard of care for unresectable hepatocellular carcinoma (HCC), demonstrating superior overall survival (OS) and progression-free survival (PFS) versus sorafenib. Real-world data are required to further evaluate effectiveness and safety.

methodsWe conducted a retrospective multicentre analysis across three oncology centres in the Midlands, UK, with audit committee approval. Eligible patients had HCC confirmed histologically where feasible.

resultsAs of August 2025, 233 patients were included, with a median follow-up of 17.4 months (95% CI: 12.6-23.2). Median OS was 16.5 months (95% CI: 14.2-20.7), with 6-month OS of 76.8%. Median PFS was 12.3 months (95% CI: 10.0-16.3), with 6-month PFS of 70.8%. The objective response rate was 42.9%. Treatment discontinuation occurred in 81.5% of patients, most commonly due to disease progression (47.4%), toxicity (22.6%), or liver decompensation (17.9%). Second-line therapy was administered to 39.1%. Any-grade adverse events occurred in 41.2%, with ≥grade 3 toxicity in 23.2%.

conclusionsIn this UK real-world cohort, ATE/BEV demonstrated survival outcomes comparable to IMBrave150, with manageable toxicity and meaningful access to subsequent therapy, supporting its effectiveness beyond clinical trial settings.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeUnited KingdomAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAtezolizumab-bevacizumabHCCImmune-related adverse eventsImmunotherapyReal-world evidence

Identifiers

PMID42477572
PMCPMC13678876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.